Official Title

Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Intervention/Treatment

    vitamin a ...
  • Study Participants

    59666
The purpose of this trial is to determine whether providing women with a weekly oral supplement of vitamin A, either preformed or as beta-carotene, at a dosage equivalent to a recommended intake from early pregnancy through three months postpartum, can reduce the risk of maternal mortality, fetal loss, or infant mortality.
Maternal mortality and vitamin A deficiency coexist in rural South Asia. In Nepal, weekly supplementation with vitamin A or beta-carotene during the child-bearing years reduced all-cause maternal mortality and, in night blind women, also infant mortality. The present trial is testing the efficacy of the same supplements from ~9 weeks' gestation to 12 weeks postpartum. The planned sample size is 68,000 pregnancies. It is being conducted in 19 rural unions, covering an area of ~750 sq km with a population of ~580,000 in Gaibandha and Southern Rangpur Districts in Northern Bangladesh. The study area was mapped as 596 "sectors" (unit of randomization), each comprising 200-275 households; ~135,000 houses were numerically addressed and, at the outset, 103,000 women were listed. Women are visited at home every 5 weeks by 596 trained female staff to detect pregnancy by a combination of menstrual history and urine testing. Newly married women are prospectively enlisted for pregnancy surveillance. Following informed consent urine-positive (pregnant) women detected during surveillance are enrolled to receive weekly a capsule containing 7000 retinol equivalents of preformed vitamin A, 42 mg of beta-carotene or placebo. Vital events are recorded weekly through 3 months postpartum. Trained interviewers conduct maternal nutritional and health and household socioeconomic assessments in the 1st trimester. At 3 months postpartum, interviewers assess both mother and infant for health and nutritional status, including apparent birth defects that are later physician-confirmed. An additional home health assessment occurs at 6 months post partum, and vital status is recorded for mother and infant at one year postpartum. A ~3% subsample of enrolled pregnant women participate in a substudy involving enhanced clinical, anthropometric, biochemical, body compositional, morbidity and interview-based assessment protocols in the 1st, 2nd and 3rd trimesters, and at 3 months post-partum. Reported maternal and infant deaths are verified and causes ascertained during "verbal autopsy" interviews with family members of the deceased.
Study Started
Aug 31
2001
Primary Completion
Jan 31
2007
Study Completion
Mar 31
2008
Results Posted
Oct 12
2011
Estimate
Last Update
Mar 07
2012
Estimate

Dietary Supplement Vitamin A or Beta-Carotene Supplements

weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy

1 Experimental

Weekly oral supplement with 7000 µg retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy

2 Experimental

Weekly oral supplement with 42 mg of beta-carotene from early pregnancy through 12 weeks following termination of pregnancy

3 Placebo Comparator

Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy

Criteria

Inclusion Criteria:

Married women of reproductive age
First pregnancy during time period of trial

Exclusion Criteria:

Premenarchial girls
Married women with a previous pregnancy enrolled into the trial
Previously married women who have moved into the study area
Single women (never married, widowers)
Women who are sterilized (or whose husbands are sterilized)
Menopausal women

Summary

1 Placebo Control

2 Vitamin A Supplement

3 Beta-Carotene Group

All Events

Event Type Organ System Event Term

All-cause, Pregnancy-related Mortality

Mortality evaluated on intent-to-treat basis

1 Placebo Control

41.0
Participants

2 Vitamin A Supplement

47.0
Participants

3 Beta-Carotene Group

50.0
Participants

Maternal Morbidity, Including Obstetric Complications

Outcome Measure Data Not Reported

Gestational Age at Birth

Outcome Measure Data Not Reported

Fetal Growth and Postnatal Infant Growth Through Three Months of Age

Outcome Measure Data Not Reported

Infant Morbidity Through 3 Months of Age

Outcome Measure Data Not Reported

Plasma Beta-carotene in the Third Trimester of Pregnancy(Nutritonal Status of the Mother)

1 Placebo Control

0.11
Plasma beta-carotene micromoles / liter (Mean)
Standard Deviation: 0.09

2 Vitamin A Supplement

0.12
Plasma beta-carotene micromoles / liter (Mean)
Standard Deviation: 0.12

3 Beta-Carotene Group

0.12
Plasma beta-carotene micromoles / liter (Mean)
Standard Deviation: 0.10

All-cause 3-month Infant Mortality

1 Placebo Control

951.0
participants

2 Vitamin A Supplement

904.0
participants

3 Beta-Carotene Group

979.0
participants

Plasma Retinol at the Third Trimester of Pregnancy (Nutritional Status of the Mother)

1 Placebo Control

1.02
micromoles per liter (Mean)
Standard Deviation: 0.31

2 Vitamin A Supplement

1.25
micromoles per liter (Mean)
Standard Deviation: 0.33

3 Beta-Carotene Group

1.06
micromoles per liter (Mean)
Standard Deviation: 0.33

Total

59666
Participants

Age Continuous

23.09
years (Mean)
Standard Deviation: 6.55

Age Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

1 Placebo Control

2 Vitamin A Supplement

3 Beta-Carotene Group

Drop/Withdrawal Reasons

1 Placebo Control

2 Vitamin A Supplement

3 Beta-Carotene Group